Pharmaceutical companies are right to challenge the mandatory pricing model in court

Whether CMS has the authority to set drug prices based on foreign benchmarks is an open legal question.

Overview Debates Related claims Topics Sources

Pharmaceutical manufacturing quality standards are sufficient to prevent particulate contamination

Placebo-controlled trials should be required before approving new medicines

Updated vaccines should undergo full clinical trials before approval

New medicines should have to outperform existing treatments before approval

Governments should license publicly funded drug patents to competitors when prices are unaffordable

Pharmaceutical companies have too much influence over healthcare

Pharmaceutical companies should prioritize rare diseases over widespread public health conditions

Million-dollar price tags for ultra-rare disease treatments are justified to incentivize drug development

Voluntary pricing agreements with drugmakers are more effective than mandatory controls

Tying Medicare drug prices to international benchmarks will lower patient costs without reducing access to treatments

The finalized international pricing model covers too few drugs to meaningfully reduce Medicare spending

Exempting drugmakers that struck voluntary price deals from the mandatory pricing model undermines the program

Serapha Bio should halt development of its SERP-01 therapy during the Beam lawsuit

Merck's lung cancer drug poses unacceptable safety risks to patients

The FDA was justified in rejecting Merck's accelerated approval bid for its lung cancer drug

The FDA should approve UniQure's AMT-130 for Huntington's disease

External control groups are reliable for evaluating experimental gene therapies

Direct-to-consumer prescription drug advertising should be banned

Medicare should cover GLP-1 drugs for all adults with obesity

The FDA should restrict barzolvolimab to a last-line therapy for chronic hives